Peripherally mediated antinociception of the μ-opioid receptor agonist 2-[(4,5α-epoxy-3-hydroxy-14β-methoxy-17-methylmorphinan-6β-yl) amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 220-227

  Bileviciute Ljungar, Indre ^a,b,d   Spetea, Mariana ^c   Guo, Yan ^a   Schütz, Johannes ^c   Windisch, Petra ^c   Schmidhammer, Helmut ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

14 METHOXYMETOPON; 17 METHYLNALOXONE; 2 [(4,5ALPHA EPOXY 3 HYDROXY 14BETA METHOXY 17 METHYLMORPHINAN 6BETA YL)AMINO]ACETIC ACID; CARRAGEENAN; HS 731; MORPHINE; MU OPIATE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INHIBITION; DRUG POTENTIATION; EXPERIMENTAL ANIMAL; HYPERALGESIA; INFLAMMATION; MALE; NONHUMAN; PAIN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; CARRAGEENAN; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; HINDLIMB; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; MALE; MORPHINANS; PAIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, MU;

EID: 33645120408     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.096032     Document Type: Article

References (40)

1. Aceto MD, Harris LS, and Bowman ER (1997) Etorphines: μ-opioid receptor-selective antinociception and low physical dependence capacity. Eur J Pharmacol 338:215-223.
2. Antonijevic I, Mousa SA, Schäfer M, and Stein C (1995) Perineural defect and peripheral opioid analgesia in inflammation. J Neurosci 15:165-172.
3. Bileviciute-Ljungar I and Lundeberg T (2000) Contralateral but not systemic administration of bupivacaine reduces acute inflammation in the rat hindpaw. Somatosens Mot Res 17:285-293.
4. Bileviciute-Ljungar I and Spetea M (2001) Contralateral but not systemic administration of κ-opioid agonist, U-50,488H, induces antinociception in acute hindpaw inflammation in rats. Br J Pharmacol 132:252-258.
5. Binder W, Machelska H, Mousa S, Schmitt T, Riviere PJ, Junien JL, Stein C, and Schäfer M (2001) Analgesic and anti-inflammatory effects of two novel κ-opioid peptides. Anesthesiology 94:1034-1044.
6. Brown DR and Goldberg LI (1985) The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 24:181-191.
7. Coggeshall RE, Zhou S, and Carlton SM (1997) Opioid receptors on peripheral sensory axons. Brain Res 764:126-132.
8. DeHaven-Hudkins DL, Burgos LC, Cassel JA, Daubert JD, DeHaven RN, Mansson E, Nagasaka H, Yu G, and Yaksh T (1999) Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 289:494-502.
9. DeHaven-Hudkins DL and Dolle RE (2004) Peripherally restricted agonists as novel analgesic agents. Curr Pharm Des 10:743-757.
10. Frances B, Gout R, Monsarrat B, Cros J, and Zajac JM (1992) Further evidence that morphine-6β-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 262:25-31.
11. Fürst S, Búzás B, Friedmann T, Schmidhammer H, and Borsodi A (1993) Highly potent novel opioid receptor agonist in the 14-alkoxymetopon series. Eur J Pharmacol 236:209-215.
12. Fürst S, Riba P, Friedmann T, Timar J, Al-Khrasani M, Obara I, Makuch W, Spetea M, Schütz J, Przewlocki R, et al. (2005) Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat. J Pharmacol Exp Ther 312:609-618.
13. Hassan AHS, Ableitner A, Stein C, and Herz A (1993) Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience 55:185-195.
14. Ji RR, Zhang Q, Law PY, Low HH, Elde R, and Hökfelt T (1995) Expression of μ-, δ-and κ-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation. J Neurosci 15:8156-8166.
15. Joris J, Costello A, Dubner R, and Hargreaves KM (1990) Opiates suppress carrageenan-induced edema and hyperthermia at doses that inhibit hyperalgesia. Pain 43:95-103.
16. King MA, Su W, Nielan C, Chang AH, Schütz J, Schmidhammer H, and Pasternak GW (2003) 14-Methoxymetopon, a very potent μ-opioid analgesic with an unusual pharmacological profile. Eur J Pharmacol 459:203-209.
17. Lötsch J and Geisslinger G (2001) Morphine-6-glucuronide: an analgesic of the future? Clin Pharmacokinet 40:485-499.
18. Lötsch J, Tegeder I, Angst MS, and Geisslinger G (2000) Antinociceptive effects of morphine-6-glucuronide in homozygous MDR1a P-glycoprotein knockout and in wildtype mice in the hotplate test. Life Sci 66:2393-2403.
19. Machelska H, Pflüger M, Weber W, Piranvisseh-Volk M, Daubert JD, DeHaven R, and Stein C (1999) Peripheral effects of the κ-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J Pharmacol Exp Ther 290:354-361.
20. MacPherson RD (2002) New directions in pain management. Drugs Today 38:135-145.
21. Millan MJ, Członkowski A, Pilcher CWT, Almeida OFX, Millan MH, Colpaert FC, and Herz A (1987) A model of chronic pain in the rat: functional correlates of alterations in the activity of opioid systems. J Neurosci 7:77-87.
22. Mousa SA, Zhang Q, Sitte N, Ji RR, and Stein C (2001) β-Endorphin-containing memory-cells and μ-opioid receptors undergo transport to peripheral inflamed tissue. J Neuroimmunol 115:71-78.
23. Perrot S, Guilbaud G, and Kayser V (1999) Effects of intraplantar morphine on paw edema and pain-related behaviour in a rat model of repeated acute inflammation. Pain 83:249-257.
24. Perrot S, Guilbaud G, and Kayser V (2001) Differential behavioural effects of peripheral and systemic morphine and naloxone in a rat model of repeated acute inflammation. Anesthesiology 94:870-875.
25. Reisine T and Pasternak G (1996) Opioid analgesics and antagonists, in The Pharmacological Basis of Therapeutics (Hardman JG, Goodman Gilman A, and Limbird LE eds) pp 521-555, McGraw-Hill Companies, New York.
26. Schäfer M, Imai Y, Uhl GR, and Stein C (1995) Inflammation enhances peripheral μ-opioid analgesia, but not μ-opioid receptor transcription in dorsal root ganglia. Eur J Pharmacol 279:165-169.
27. Schmidhammer H, Schratz A, and Mitterdorfer J (1990) Synthesis and biological evaluation of 14-alkoxymorphinans. 8. 14-Methoxymetopon, an extremely potent opioid agonist. Helv Chim Acta 73:1784-1787.
28. Schütz J, Brandt W, Spetea M, Wurst K, Wunder G, and Schmidhammer H (2003) Synthesis of 6-amino acid substituted derivatives of the highly potent analgesic 14-O-methyloxymorphone. Helv Chim Acta 86:2142-2148.
29. Selley DE, Breivogel CS, and Childers SR (1993) Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G-proteins. Mol Pharmacol 44:731-741.
30. Shaqura MA, Zöllner C, Mousa SA, Stein C, and Schäfer M (2004) Characterization of μ opioid receptor binding and G-protein coupling in rat hypothalamus, spinal cord and primary afferent neurons during inflammatory pain. J Pharmacol Exp Ther 308:712-718.
31. Spetea M, Friedmann T, Riba P, Schütz J, Wunder G, Langer T, Schmidhammer H, and Fürst S (2004) In vitro opioid activity profiles of 6-amino acid substituted derivatives of 14-O-methyloxymorphone. Eur J Pharmacol 483:301-308.
32. 3H]14-methoxymetopon, a high affinity μ-opioid receptor agonist. Eur J Neurosci 18:290-295.
33. Stein C, Machelska H, Binder W, and Schäfer M (2001) Peripheral opioid analgesia. Curr Opin Pharmacol 1:62-65.
34. Stein C, Millan MJ, Shippenberg TS, and Herz A (1988) Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci Lett 84:225-228.
35. Stein C, Millan MJ, Shippenberg TS, Peter K, and Herz A (1989) Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of μ, δ and κ receptors. J Pharmacol Exp Ther 248:1269-1275.
36. Stein C, Schäfer M, and Machelska H (2003) Attaching pain at its source: new perspectives on opioids. Nat Med 9:1003-1008.
37. Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, and Lötsch J (2003) Peripheral opioid analgesia in experimental human pain models. Brain 126:1092-1102.
38. Walker J, Catheline G, and Kayser V (1999) Lack of cross-tolerance between the antinociceptive effects of systemic morphine and asimadoline, a peripherally-selective κ-opioid agonist, in CCI-neuropathic rats. Pain 83:509-516.
39. Zernig G, Saria A, Krassnig R, and Schmidhammer H (2000) Signal transduction efficacy of the highly potent μ-opioid agonist 14-methoxymetopon. Life Sci 66:1871-1877.
40. Zöllner C, Shaqura MA, Bopaiah CP, Mousa S, Stein C, and Schäfer M (2003) Painful inflammation-induced increase in μ-opioid receptor binding and G-protein coupling in primary afferent neurons. Mol Pharmacol 64:202-210.